Targeting HSF1 disrupts HSP90 chaperone function in chronic lymphocytic leukemia

Siddhartha Ganguly, Trisha Home, Abdulraheem Yacoub, Suman Kambhampati, Huidong Shi, Prasad Dandawate, Subhash Padhye, Ashok K. Saluja, Joseph McGuirk, Rekha Rao

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

CLL is a disease characterized by chromosomal deletions, acquired copy number changes and aneuploidy. Recent studies have shown that overexpression of Heat Shock Factor (HSF) 1 in aneuploid tumor cells can overcome deficiencies in heat shock protein (HSP) 90-mediated protein folding and restore protein homeostasis. Interestingly, several independent studies have demonstrated that HSF1 expression and activity also affects the chaperoning of HSP90 kinase clients, although the mechanism underlying this observation is unclear. Here, we determined how HSF1 regulates HSP90 function using CLL as a model system. We report that HSF1 is overexpressed in CLL and treatment with triptolide (a small molecule inhibitor of HSF1) induces apoptosis in cultured and primary CLL B-cells. We demonstrate that knockdown of HSF1 or its inhibition with triptolide results in the reduced association of HSP90 with its kinase co-chaperone cell division cycle 37 (CDC37), leading to the partial depletion of HSP90 client kinases, Bruton's Tyrosine Kinase (BTK), c-RAF and cyclin-dependent kinase 4 (CDK4). Treatment with triptolide or HSF1 knockdown disrupts the cytosolic complex between HSF1, p97, HSP90 and the HSP90 deacetylase- Histone deacetylase 6 (HDAC6). Consequently, HSF1 inhibition results in HSP90 acetylation and abrogation of its chaperone function. Finally, tail vein injection of Mec- 1 cells into Rag2-/-IL2Rγc-/- mice followed by treatment with minnelide (a pro-drug of triptolide), reduced leukemia, increased survival and attenuated HSP90-dependent survival signaling in vivo. In conclusion, our study provides a strong rationale to target HSF1 and test the activity of minnelide against human CLL.

Original languageEnglish (US)
Pages (from-to)31767-31779
Number of pages13
JournalOncotarget
Volume6
Issue number31
DOIs
StatePublished - Jan 1 2015

Fingerprint

B-Cell Chronic Lymphocytic Leukemia
Phosphotransferases
Aneuploidy
Cyclin-Dependent Kinase 4
HSP90 Heat-Shock Proteins
Histone Deacetylases
Survival
Protein Folding
Prodrugs
Acetylation
Tail
Veins
Shock
Cell Cycle
Leukemia
Homeostasis
B-Lymphocytes
Therapeutics
Hot Temperature
Apoptosis

Keywords

  • CLL
  • HSF1
  • HSP90
  • Minnelide

ASJC Scopus subject areas

  • Oncology

Cite this

Ganguly, S., Home, T., Yacoub, A., Kambhampati, S., Shi, H., Dandawate, P., ... Rao, R. (2015). Targeting HSF1 disrupts HSP90 chaperone function in chronic lymphocytic leukemia. Oncotarget, 6(31), 31767-31779. https://doi.org/10.18632/oncotarget.5167

Targeting HSF1 disrupts HSP90 chaperone function in chronic lymphocytic leukemia. / Ganguly, Siddhartha; Home, Trisha; Yacoub, Abdulraheem; Kambhampati, Suman; Shi, Huidong; Dandawate, Prasad; Padhye, Subhash; Saluja, Ashok K.; McGuirk, Joseph; Rao, Rekha.

In: Oncotarget, Vol. 6, No. 31, 01.01.2015, p. 31767-31779.

Research output: Contribution to journalArticle

Ganguly, S, Home, T, Yacoub, A, Kambhampati, S, Shi, H, Dandawate, P, Padhye, S, Saluja, AK, McGuirk, J & Rao, R 2015, 'Targeting HSF1 disrupts HSP90 chaperone function in chronic lymphocytic leukemia', Oncotarget, vol. 6, no. 31, pp. 31767-31779. https://doi.org/10.18632/oncotarget.5167
Ganguly S, Home T, Yacoub A, Kambhampati S, Shi H, Dandawate P et al. Targeting HSF1 disrupts HSP90 chaperone function in chronic lymphocytic leukemia. Oncotarget. 2015 Jan 1;6(31):31767-31779. https://doi.org/10.18632/oncotarget.5167
Ganguly, Siddhartha ; Home, Trisha ; Yacoub, Abdulraheem ; Kambhampati, Suman ; Shi, Huidong ; Dandawate, Prasad ; Padhye, Subhash ; Saluja, Ashok K. ; McGuirk, Joseph ; Rao, Rekha. / Targeting HSF1 disrupts HSP90 chaperone function in chronic lymphocytic leukemia. In: Oncotarget. 2015 ; Vol. 6, No. 31. pp. 31767-31779.
@article{89638115e3b44b389fc32e2c9bbe70ae,
title = "Targeting HSF1 disrupts HSP90 chaperone function in chronic lymphocytic leukemia",
abstract = "CLL is a disease characterized by chromosomal deletions, acquired copy number changes and aneuploidy. Recent studies have shown that overexpression of Heat Shock Factor (HSF) 1 in aneuploid tumor cells can overcome deficiencies in heat shock protein (HSP) 90-mediated protein folding and restore protein homeostasis. Interestingly, several independent studies have demonstrated that HSF1 expression and activity also affects the chaperoning of HSP90 kinase clients, although the mechanism underlying this observation is unclear. Here, we determined how HSF1 regulates HSP90 function using CLL as a model system. We report that HSF1 is overexpressed in CLL and treatment with triptolide (a small molecule inhibitor of HSF1) induces apoptosis in cultured and primary CLL B-cells. We demonstrate that knockdown of HSF1 or its inhibition with triptolide results in the reduced association of HSP90 with its kinase co-chaperone cell division cycle 37 (CDC37), leading to the partial depletion of HSP90 client kinases, Bruton's Tyrosine Kinase (BTK), c-RAF and cyclin-dependent kinase 4 (CDK4). Treatment with triptolide or HSF1 knockdown disrupts the cytosolic complex between HSF1, p97, HSP90 and the HSP90 deacetylase- Histone deacetylase 6 (HDAC6). Consequently, HSF1 inhibition results in HSP90 acetylation and abrogation of its chaperone function. Finally, tail vein injection of Mec- 1 cells into Rag2-/-IL2Rγc-/- mice followed by treatment with minnelide (a pro-drug of triptolide), reduced leukemia, increased survival and attenuated HSP90-dependent survival signaling in vivo. In conclusion, our study provides a strong rationale to target HSF1 and test the activity of minnelide against human CLL.",
keywords = "CLL, HSF1, HSP90, Minnelide",
author = "Siddhartha Ganguly and Trisha Home and Abdulraheem Yacoub and Suman Kambhampati and Huidong Shi and Prasad Dandawate and Subhash Padhye and Saluja, {Ashok K.} and Joseph McGuirk and Rekha Rao",
year = "2015",
month = "1",
day = "1",
doi = "10.18632/oncotarget.5167",
language = "English (US)",
volume = "6",
pages = "31767--31779",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "31",

}

TY - JOUR

T1 - Targeting HSF1 disrupts HSP90 chaperone function in chronic lymphocytic leukemia

AU - Ganguly, Siddhartha

AU - Home, Trisha

AU - Yacoub, Abdulraheem

AU - Kambhampati, Suman

AU - Shi, Huidong

AU - Dandawate, Prasad

AU - Padhye, Subhash

AU - Saluja, Ashok K.

AU - McGuirk, Joseph

AU - Rao, Rekha

PY - 2015/1/1

Y1 - 2015/1/1

N2 - CLL is a disease characterized by chromosomal deletions, acquired copy number changes and aneuploidy. Recent studies have shown that overexpression of Heat Shock Factor (HSF) 1 in aneuploid tumor cells can overcome deficiencies in heat shock protein (HSP) 90-mediated protein folding and restore protein homeostasis. Interestingly, several independent studies have demonstrated that HSF1 expression and activity also affects the chaperoning of HSP90 kinase clients, although the mechanism underlying this observation is unclear. Here, we determined how HSF1 regulates HSP90 function using CLL as a model system. We report that HSF1 is overexpressed in CLL and treatment with triptolide (a small molecule inhibitor of HSF1) induces apoptosis in cultured and primary CLL B-cells. We demonstrate that knockdown of HSF1 or its inhibition with triptolide results in the reduced association of HSP90 with its kinase co-chaperone cell division cycle 37 (CDC37), leading to the partial depletion of HSP90 client kinases, Bruton's Tyrosine Kinase (BTK), c-RAF and cyclin-dependent kinase 4 (CDK4). Treatment with triptolide or HSF1 knockdown disrupts the cytosolic complex between HSF1, p97, HSP90 and the HSP90 deacetylase- Histone deacetylase 6 (HDAC6). Consequently, HSF1 inhibition results in HSP90 acetylation and abrogation of its chaperone function. Finally, tail vein injection of Mec- 1 cells into Rag2-/-IL2Rγc-/- mice followed by treatment with minnelide (a pro-drug of triptolide), reduced leukemia, increased survival and attenuated HSP90-dependent survival signaling in vivo. In conclusion, our study provides a strong rationale to target HSF1 and test the activity of minnelide against human CLL.

AB - CLL is a disease characterized by chromosomal deletions, acquired copy number changes and aneuploidy. Recent studies have shown that overexpression of Heat Shock Factor (HSF) 1 in aneuploid tumor cells can overcome deficiencies in heat shock protein (HSP) 90-mediated protein folding and restore protein homeostasis. Interestingly, several independent studies have demonstrated that HSF1 expression and activity also affects the chaperoning of HSP90 kinase clients, although the mechanism underlying this observation is unclear. Here, we determined how HSF1 regulates HSP90 function using CLL as a model system. We report that HSF1 is overexpressed in CLL and treatment with triptolide (a small molecule inhibitor of HSF1) induces apoptosis in cultured and primary CLL B-cells. We demonstrate that knockdown of HSF1 or its inhibition with triptolide results in the reduced association of HSP90 with its kinase co-chaperone cell division cycle 37 (CDC37), leading to the partial depletion of HSP90 client kinases, Bruton's Tyrosine Kinase (BTK), c-RAF and cyclin-dependent kinase 4 (CDK4). Treatment with triptolide or HSF1 knockdown disrupts the cytosolic complex between HSF1, p97, HSP90 and the HSP90 deacetylase- Histone deacetylase 6 (HDAC6). Consequently, HSF1 inhibition results in HSP90 acetylation and abrogation of its chaperone function. Finally, tail vein injection of Mec- 1 cells into Rag2-/-IL2Rγc-/- mice followed by treatment with minnelide (a pro-drug of triptolide), reduced leukemia, increased survival and attenuated HSP90-dependent survival signaling in vivo. In conclusion, our study provides a strong rationale to target HSF1 and test the activity of minnelide against human CLL.

KW - CLL

KW - HSF1

KW - HSP90

KW - Minnelide

UR - http://www.scopus.com/inward/record.url?scp=84945537222&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84945537222&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.5167

DO - 10.18632/oncotarget.5167

M3 - Article

C2 - 26397138

AN - SCOPUS:84945537222

VL - 6

SP - 31767

EP - 31779

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 31

ER -